Chloe Atreya, MD, PHD
Medical Oncology Physician in San Francisco, California. This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 3,792 in Medical Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Chloe Atreya, MD, PHD reported a CMS MIPS final score of 74.5/100 - below the 83.1 national average - and filed 162 Medicare Part D claims in 2023.
- 74.5/100
- MIPS score · -9 vs avg
- 162
- Part D claims, 2023
- 72%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Chloe Atreya, MD, PHD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
75 12th percentile higher than 12% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Chloe Atreya, MD, PHD sits
This provider among medical oncology physician peers
Across the 1,527 medical oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Chloe Atreya, MD, PHD writes more Part D claims than 22% of them and scores higher on MIPS quality than 9% - placing this provider in the lower-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one medical oncology physician peer from a representative sample of 60; the gold marker is Chloe Atreya, MD, PHD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Chloe Atreya, MD, PHD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 3 hospital affiliations - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Chloe Atreya, MD, PHD?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in California
How Medical Oncology Physician compares to other specialties among California providers
Largest specialties in California (% of in-state providers)
Medical Oncology Physician ranks #177 among California's specialties (0% of in-state providers)
Each bar is a specialty's share of the California provider total, by primary NUCC taxonomy. The highlighted bar is Medical Oncology Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Chloe Atreya, MD, PHD's 2023 MIPS final score plotted against the Medical Oncology Physician national average
- MIPS Final Score
- 74.5/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Medical Oncology Physician) - 74.5/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Cost dim CMS Cost category
- Specialty volume Medical Oncology Physician US NPIs
74.5/100 MIPS final score - 8.6 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Medical Oncology Physician. Cost dim: 46.7.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Chloe Atreya, MD, PHD appears in the CMS NPPES registry as a Medical Oncology Physician provider holding MD, PHD credentials at 1600 DIVISADERO ST, San Francisco, CA, 94115, with a listed phone of (415) 353-9888. NPI 1326058777 was issued on 08/08/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what Atreya most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 162 prescription claims written by this provider, covering 25 Medicare beneficiaries and totaling roughly $729K in drug spend, split 28% brand-name and 72% generic by claim count. These figures capture only Medicare Part D, commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 74.5/100 for the 2023 performance year, compared with the national average of 83.1.
Medical Oncology Physician is a narrow specialty nationwide, with 3,792 enrolled providers across 53 states and an average of 689 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1326058777 |
|---|---|
| Specialty | Medical Oncology Physician |
| Credentials | MD, PHD |
| Gender | Female |
| NPI Issued | 08/08/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Chloe Atreya, MD, PHD's current license status, disciplinary history, and board certifications with the Medical Board of California in California before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where Chloe Atreya, MD, PHD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
According to CMS billing records, Chloe Atreya, MD, PHD is affiliated with 3 Medicare-billing facilities.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Chloe Atreya, MD, PHD. Source: openpaymentsdata.cms.gov.
Total received
$2.9K
Largest payer
F. Hoffmann-La Roche AG
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Chloe Atreya, MD, PHD. To verify Chloe Atreya, MD, PHD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
28% brand-name claims vs 72% generic, on 162 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 185
- Total Day Supply
- 4,817
- Brand vs Generic
- 28% brand / 72% generic
- Brand Drug Cost
- $482K
- Generic Drug Cost
- $247K
- Antibiotic Claims
- 13
Patient Demographics
- Average Patient Age
- 70.5 years
- Avg HCC Risk Score
- 2.67
- Gender Split
- 56% female / 44% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Chloe Atreya, MD, PHD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Imatinib Mesylate
Imatinib Mesylate
32 claims
- Sunitinib Malate
Sunitinib Malate
23 claims
- Lonsurf
Lonsurf
20 claims
- Prochlorperazine M…
Prochlorperazine Maleate
14 claims
- Doxycycline Hyclate 11
Doxycycline Hyclate
11 claims
- Ondansetron Hcl 11
Ondansetron Hcl
11 claims
| Drug | Claims |
|---|---|
| Imatinib Mesylate | 32 |
| Sunitinib Malate | 23 |
| Lonsurf Trifluridine/Tipiracil Hcl | 20 |
| Prochlorperazine Maleate | 14 |
| Doxycycline Hyclate | 11 |
| Ondansetron Hcl | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Medical Oncology Physician Overview
How Chloe Atreya, MD, PHD fits within the Medical Oncology Physician landscape nationally.
Chloe Atreya, MD, PHD's 162 claims are below the specialty average of 689.
Nearby Medical Oncology Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Atreya.
Compare Medical Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Medical Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore California
Frequently Asked Questions
What is Chloe Atreya, MD, PHD's specialty? ▼
How much does Chloe Atreya, MD, PHD prescribe under Medicare Part D? ▼
What is Chloe Atreya, MD, PHD's Medicare quality score? ▼
Where is Chloe Atreya, MD, PHD located? ▼
What is Chloe Atreya, MD, PHD's NPI number? ▼
Does Chloe Atreya, MD, PHD prescribe more brand-name or generic drugs? ▼
How many Medical Oncology Physician providers are there in the US? ▼
What drugs does Chloe Atreya, MD, PHD prescribe most often? ▼
Does Chloe Atreya, MD, PHD accept Medicare? ▼
How can I verify Chloe Atreya, MD, PHD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology